
Experience
LB Pharmaceuticals Announces $285 Million Upsized IPO
September 12, 2025
Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).
Related contacts
Related Practices & Industries
Infleqtion to Go Public Through Merger With Churchill Capital Corp X
September 8, 2025
Cooley advised Infleqtion, a global leader in neutral atom-based quantum technology, on its definitive business combination agreement with Churchill Capital Corp X, with the aim to accelerate Infleqtion’s mission to commercialize quantum products that provide orders of magnitude improvement in computing and precision sensing applications.
Related contacts
Related Practices & Industries
Framer Secures $100 Million Series D
August 28, 2025
Cooley advised Framer, a professional website design platform that has quickly become the platform of choice for companies that want to ship their entire .com, on its $100 million Series D financing.
Related contacts
Related Practices & Industries
MannKind to Acquire scPharmaceuticals for up to $360 Million
August 25, 2025
Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million
Related contacts
Related Practices & Industries
EliseAI Secures $250 Million Series E
August 20, 2025
Cooley advised EliseAI, an artificial intelligence company automating complex healthcare and housing systems, on the close of its $250 million Series E financing.
Related contacts
Related Practices & Industries
Related news and events
Infleqtion to Go Public Through Merger With Churchill Capital Corp X
Admissions and credentials
California